Examining 3 major risk factors of AMD

Video

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Joshua Mali, MD, retina medical director, Macular Degeneration Association; vitreoretinal surgeon at The Eye Associates (Sarasota, FL); founder, CEO, Mali Enterprises, discusses the three major risk factors for developing age-related macular degeneration (AMD).

See more AMD Awareness content here, here, and here.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Dr Ali Erginay discusses his EURETINA presentation
Varun Chaudhary speaks with David Hutton about the 2023 EURETINA congress
Related Content
A patient covers her eye to perform a Snellen chart test as the optometrist looks on. Image credit: ©megaflopp – stock.adobe.com

New research data reflect patient satisfaction following faricimab treat-and-extend regimen

December 5th 2023
Article

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

An optometrist examines an elderly patient's eyes. Image credit: ©Nadia L/peopleimages.com – stock.adobe.com

Prevent Blindness participates in first-ever World Geographic Atrophy Day

December 5th 2023
Article

In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals

An eyeball with a view of the globe imposed on the iris. Image credit: ©Chris Tefme – stock.adobe.com

A global view of diabetic eye disease

December 4th 2023
Article

At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research

Marco A. Zarbin, MD, PhD, Professor of Ophthalmology, Rutgers New Jersey Medical School

AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials

November 24th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

Documents indicate a corporation filing for bankruptcy. Image credit: ©Minerva Studio – stock.adobe.com

Oxurion NV will file for bankruptcy following KALAHARI data release

November 20th 2023
Article

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Intraoperative fluorescein angiography with fluorescein mode, patient with pars planitis with peripheral leakage.

The future is now: Innovations in vitreoretinal surgery 3D viewing systems and robotics

November 16th 2023
Article

Developing technology may offer marked improvements in surgical precision

© 2023 MJH Life Sciences

All rights reserved.